Imaging Management, Volume 2 - Issue 2, Winter 2008

CV Therapeutics Announces License Agreement

The Menari Group have been granted exclusive rights to Ranexa. The agreement grants rights to Menarini for Ranexa in 68 countries, including the 27 countries of the European Union, the Commonwealth of Independent States and certain countries in Central and South America. The deal included an upfront payment of 70 million dollars and further payments could amount to 315 million dollars.
Ranexa will be launched to specialists and primary care physicians. It is approved for use in Europe as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to firstline antianginal therapies.

Print as PDF
The Menari Group have been granted exclusive rights to Ranexa. The agreement grants rights to Menarini for Ranexa in 68 countries, including the 27 countri

No comment


Please login to leave a comment...